linjc16/ctgov huggingface dataset:
Vitamin D Influence on Oocyte Donation

Study Overview
=================
Brief Summary
-----------------
Objective: To investigate the correlation between total and bioavailable serum 25-OH vitamin D, ovarian reserve and ovarian response to controlled stimulation in egg donors.

Detailed Description
-----------------
Design: Retrospective study. Setting: University affiliated private IVF center. Intervention: Serum analysis of vitamin D, bioavailable vitamin D, antimullerian hormone (AMH), antral follicular count (AFC), reproductive outcome of oocytes recipients Main outcome measure: AMH, AFC, number of oocytes retrieved and number of mature oocytes, pregnancy and implantation rate of donated oocytes'recipients.

Official Title
-----------------
Impact of Vitamin D Levels on Ovarian Reserve and Ovarian Response to Controlled Stimulation in Egg Donors

Conditions
-----------------
Disorder of Phosphate, Calcium and Vitamin D Metabolism, Female Infertility Due to Diminished Ovarian Reserve, Hormonal Requirement, Reproductive Disorder

Intervention / Treatment
-----------------
* Other: vitamin D,AMH, AFC, reproductive outcome egg recipients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasian race, between 18 and 34 years of age, all donors had normal menstrual cycles of 26-34 days, normal weight range (BMI 18- 25 Kg/m2), normal uterus and ovaries on transvaginal ultrasound (no signs of polycystic ovarian syndrome), and an antral follicle count (AFC) >10, normal karyotype Exclusion Criteria: current or past exposure to radiation or hazardous chemical substances, history of drug use, family history of hereditary chromosomal diseases, sexually transmitted diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 34 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of oocytes retrieved |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implantation rate |  | 2 months | 
| pregnancy rate |  | 2 months | 
| AFC |  | 2 months | 
| number of mature oocytes |  | 2 months | 
| AMH |  | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Egg donation, vitaminD, ovarian reserve, ovarian stimulation
Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire

Study Overview
=================
Brief Summary
-----------------
75 heterosexual women are asked to use 3 different types of contraception (Nuvaring, low-dose combination pill, minipill), each during 3 months. On a monthly basis, questionnaires are filled out about sexual desire and psychosocial, relational en sexual parameters. Also the sexual desire of the partner is questioned. On a three-monthly basis, blood samples are drawn to determine changes in hormonal parameters (one sample per product period). 75 lesbian women are doing the same trial, but during an extra 3 months period, they are asked to have their natural menstrual cyclus as a control condition. Blood samples during these extra months will be drawn at the third or fourth day after start of the menses.

Official Title
-----------------
Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Nuvaring
* Drug: low-dose combination pill
* Drug: minipill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heterosexual or lesbian women Aged between 18 and 45 years Stable monogameous relationship Normal menstrual cyclus Exclusion Criteria: Polycystic ovarial syndrome Normal exclusion criteria for the use of contraception Use of medication known to influence sexual desire and/or androgen levels Women who wants to become pregnant, are pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nuvaring|nan|
|Drug: low-dose combination pill|nan|
|Drug: minipill|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parameters about sexual desire and psychosocial, relational en sexual parameters. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy women
Soft Tissue Assessment in Screw-Retained Maxillary Complete Denture With Electric Welded Framework Versus Casted

Study Overview
=================
Brief Summary
-----------------
comparing the changes in the soft tissue around the implants that will be joined by a metal framework either with electric welding or with the conventional casting method

Detailed Description
-----------------
as joining multiple implants by a metal framework considered a solid solution for edentulous arches , but in the same time the conventional method to weld this metal framework to the implants by casting technique in lab usually involves a several disadvantages eg. cost and time consuming in addition to laboratory errors, Thus , this study aims to find another method to weld the metal framework intraorally by an electric welding device

Official Title
-----------------
Soft Tissue Changes Assessment in Screw-Retained Maxillary Implant Supported Complete Denture With Electric Welded Metal Framework Versus Casted One (RCT, Split Mouth Design)

Conditions
-----------------
Peri-Implantitis

Intervention / Treatment
-----------------
* Device: Electric intraoral welding device
* Device: casting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages range from 45 to 65 years old. Absence of any medical disorder that could complicate the Surgical phase or affect osseointegration. The patients must be completely edentulous. The patient must have enough bone height for implants minimum length of 10mm and a minimum diameter of 5 mm. Patients with good oral hygiene. Complete denture wearer. Adequate inter arch space for screw retained prosthesis. Absence of any intra-oral pathological condition. Exclusion Criteria: Patients with recent extraction(less than three months). Patients with inflamed ridge or candida infection. Patients with flappy ridge. Parafunctional habits.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: electric welded metal framework<br> | Device: Electric intraoral welding device<br>* welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally<br>|
| Experimental: conventional casted metal framework<br> | Device: casting<br>* casting the metal framework<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Soft Tissue Changes Assessment | Primary outcome is the probing depth which will be measured using the periodontal probe (unit mm) around the implant to check the changes that may occur in the peri-implant soft tissues | 12 months |
Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

Study Overview
=================
Brief Summary
-----------------
This retrospective database study analyzed resource utilization and costs associated with sitagliptin (STG) in comparison with rosiglitazone (RSG) added to metformin (MET) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large US healthcare plan.

Official Title
-----------------
Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Rosiglitazone + Metformin
* Drug: Sitagliptin + Metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Continuously enrolled in the health insurance plan to ensure complete claims coverage At least 1 claim with a diagnosis of diabetes (ICD-9 250.xx) Aged 18 years or older at the index date At least 6 months of baseline period prior to the index date At least 1 claim for MET during the baseline period At least 180 days of continuous therapy with RSG+MET or STG+MET after the index date Exclusion Criteria: At least 1 claim for insulin or sulfonylurea in the baseline period At least 1 claim with a diagnosis of congestive heart failure in the baseline period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults with Type 2 Diabetes<br>Subjects with a diagnosis (ICD-9 code) of diabetes | Drug: Rosiglitazone + Metformin<br>* At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG<br>* Other names: Avandia(TM);Drug: Sitagliptin + Metformin<br>* At least 180 days of continuous therapy with STG+MET after the first Rx for STG<br>* Other names: Januvia(R);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| medical resource utilization | Direct healthcare and indirect sick leave costs | at least 12 months following first prescription with RSG or STG as an add-on therapy to MET monotherapy. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retrospective, Type 2 Diabetes, Cost Analysis, Rosiglitazone, Sitagliptin
Intracranial Pressure (ICP) Monitoring Following Traumatic Brain Injury (TBI)

Study Overview
=================
Brief Summary
-----------------
The aim of this retrospective cohort study is to evaluate complications rates, indications, and the utility of follow-up imaging studies of ICP measurement in severe TBI patients.

Official Title
-----------------
Intracranial Pressure Monitoring Following Traumatic Brain Injury - Evaluation of Indications, Complications, and Significance of Follow-up Imaging.

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Procedure: Invasive ICP monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe Traumatic Brain Injury (GCS<9 on arrival) Implantation of invasive intracranial parenchymal ICP monitoring Exclusion Criteria: incomplete data records

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TBI patients with ICP monitoring<br>Patients with severe TBI (GCS<9 on arrival) receiving invasive ICP monitoring | Procedure: Invasive ICP monitoring<br>* Insertion of a parenchymal pressure measuring probe<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications | Intervention-related complications | up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical outcome | Outcome at discharge measured by the Glasgow Outcome Scale (GOS), range 1(death) - 5 (good recovery) | up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial pressure monitoring
Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure

Study Overview
=================
Brief Summary
-----------------
The primary purpose of the trial is to assess how effective pregabalin, alprazolam, and placebo are at reducing anxiety levels of subjects who take a dose of these treatments 4 hours before a scheduled dental procedure.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Of The Anxiolytic Efficacy Of Pregabalin And Alprazolam IR In Subjects With Anxiety Prior To Dental Procedure

Conditions
-----------------
Dental Anxiety

Intervention / Treatment
-----------------
* Drug: Pregabalin
* Drug: Alprazolam
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female outpatients 18 years of age or older who score 12 points or more on the Dental Anxiety Scale at screening and baseline evaluations and have a scheduled appointment for an elective dental procedure. Exclusion Criteria: Current diagnosis of any of the DSM-IV anxiety disorders. Current diagnosis of major depressive disorder, dysthymia, schizophrenia or any other psychotic disorder, bipolar disorder, and eating disorders as assessed by the M.I.N.I. at screening, or current diagnosis of delirium, dementia, or body dysmorphic disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pregabalin|nan|
|Drug: Alprazolam|nan|
|Drug: Placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline to endpoint on the Visual Analogue Scale for Anxiety. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The changes from baseline to endpoint, and changes from baseline to each rating timepoint differ among the three treatment groups for the VAS-Anxiety, VAS-Sedation, Time to Onset of Activity Scales scores, and, Dental Anxiety scales. |  |  |
Consistency Between Measures of Renal Function in ICU Patients

Study Overview
=================
Brief Summary
-----------------
This study aim to compare different measures of renal function (glomerular filtration rate) in ICU patients.

Detailed Description
-----------------
The study uses a large dataset of prospectively collected data according to clinical routines.

Official Title
-----------------
Consistency Between Measures of Renal Function in ICU Patients

Conditions
-----------------
Critical Illness

Intervention / Treatment
-----------------
* Diagnostic Test: S Creatinine concentration
* Diagnostic Test: Serum Cystatin C concentration
* Diagnostic Test: Urinary Creatinine Clearance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patients with at least one measurement of urinary creatinine clearance Exclusion Criteria: Renal replacement therapy initiated before the measurement of creatinine clerance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: S Creatinine concentration|nan|
|Diagnostic Test: Serum Cystatin C concentration|nan|
|Diagnostic Test: Urinary Creatinine Clearance|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlations between estimates of renal function |  | 7 days | 
| Correlations between changes in estimates of renal function |  | 7 days |
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The objective is to compare the progression of Atrial Fib (AF) burden by continuous monitoring in patients with recently diagnosed paroxysmal AF treated by catheter ablation (PVI) versus anti-arrhythmic drug (AAD) therapy.

Detailed Description
-----------------
Randomized, multicenter clinical trial comparing medical therapy (Group I) with ablation therapy(Group II). Randomization will be determined by opening a sealed envelope. All patients will be implanted with an implantable loop recorder and followed every three months.

Official Title
-----------------
Randomized Comparison of Catheter Ablation Versus Anti-arrhythmic Drug Therapy in Patients With Recently Diagnosed Paroxysmal Atrial Fibrillation as Assessed by a Continuous Implantable Monitor

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Antiarrhythmic drug
* Procedure: Catheter ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with recently diagnosed paroxysmal AF who are eligible to receive specific rhythm control therapy Exclusion Criteria: Previous treatment with Class IC or class III AAD Previous AF ablation procedure Congestive heart failure (NYHA III-IV functional class) Left Ventricle ejection fraction less than 35% Left atrial diameter > 55mm Unwillingness to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Antiarrhythmic drug<br>Class I or III antiarrhythmic drug | Drug: Antiarrhythmic drug<br>* propafenone, flecainide, sotalol, dofetilide<br>* Other names: Rhythmol, Tambocor, Betapace, Tikosyn;|
| Experimental: Catheter ablation<br>Pulmonary vein isolation | Procedure: Catheter ablation<br>* Complete PVI<br>* Other names: Thermocool;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of AF burden | The percentage of AF burden defined through continuous monitoring using an implnatage loop recorder (ILR) | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-death death | All-cause death, thromboembolic events, hospitalizations, procedural complications, drug adverse effects, and number of crossovers | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catheter ablation
Biochip for HCMV Detection in Breast Milk

Study Overview
=================
Brief Summary
-----------------
Human cytomegalovirus (HCMV) is the leading cause of neonatal viral infection and can have a significant impact on the neurosensory development of newborns and especially preterm infants. HCMV infection may result from maternal-fetal transmission during pregnancy or postnatal transmission. While congenital HCMV infection affects about 2-5% of very preterm infants, the risk of postnatal infection, particularly through breast milk, is much higher in this population (prevalence of about 20%). Many learned societies wonder about the interest to inactivate HCMV (by freezing or pasteurization) in breast milk in order to reduce or eliminate contamination of these children. However, freezing is relatively inefficient to reduce contamination and pasteurization drastically alters the nutritional quality of the milk. Therefore, a systematic preventive treatment of breast milk for very preterm infants is not currently recommended. An alternative approach could consist in detecting HCMV in breast milk to target at-risk situations. This detection can be performed by PCR but its cost and the time required to obtain the result prohibits its use for a mass detection. Currently, viral status of breast milk is not explored in practice and, depending on the health centers, breastfeeding is continued as such or milk is systematically inactivated.The main objective of VIRUMILK is to study the feasibility of the CMV detection in breast milk from lactating mothers with a biochip.The ultimate goal is to prevent postnatal HCMV infection of preterm newborns less than 33 weeks.

Official Title
-----------------
Biochip for HCMV Detection in Breast Milk From Lactating Women of Preterm Infants Less Than 33 Weeks

Conditions
-----------------
Cytomegalovirus Infections, Breast Feeding, Premature Birth of Newborn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lactating women (> 18 years) Mothers with infants less than 33 weeks hospitalized in intensive care infant / neonatal the University Hospital of Besancon. No opposition mothers. Join a French social security or receiving such a scheme. Subjects who received medical care during pregnancy. Exclusion Criteria: Legal incapacity or limited legal capacity. Topics without health insurance. Topics being in the disqualification of another study or under the national register of volunteers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| optical detection of HCMV specifically captured on the biochip with respect to the reference (PCR) technique. |  | Within 4 days after receiving the breast milk sample |